{'fraction_non_alphanumeric': 0.014925373134328358, 'fraction_numerical': 0.0, 'mean_word_length': 5.438356164383562, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
GSK and CEPI partner on coronavirus vaccine

To aid the effort to develop a vaccine for the novel coronavirus that originated in China, GlaxoSmithKline has agreed to make its vaccine adjuvant technology available to the nonprofit Coalition for Epidemic Preparedness Innovation. CEPI-funded groups developing vaccines for the virus—such as the University of Queensland—will have access to GSK adjuvants. Adjuvants are chemicals added to vaccines to boost their efficacy.